Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Kevin J Harrington"'
Autor:
Timothy Kottke, Laura Evgin, Christopher B. Driscoll, Phonphimon Wongthida, Jill Thompson, Brady Zell, Adel Samson, Jason M. Tonne, Amanda L. Huff, Lewis R. Roberts, Elizabeth Ilett, Peter Selby, Alan Melcher, Kevin J. Harrington, Jacob van Vloten, Mitesh J. Borad, Hardev Pandha, Matthew Schuelke, Richard G. Vile, Mark A. McNiven, Victoria A. Jennings, Jose S. Pulido
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
Nature Communications
Nature Communications
In our clinical trials of oncolytic vesicular stomatitis virus expressing interferon beta (VSV-IFNβ), several patients achieved initial responses followed by aggressive relapse. We show here that VSV-IFNβ-escape tumors predictably express a point-m
Autor:
M. Denyer, Nicola E. Annels, Guy Simpson, Kevin J. Harrington, Richard G. Vile, Mehreen Arif, Hardev Pandha, Alan Melcher, Matthew C. Coffey
Publikováno v:
Molecular Therapy Oncolytics
Molecular Therapy: Oncolytics, Vol 20, Iss, Pp 434-446 (2021)
Molecular Therapy: Oncolytics, Vol 20, Iss, Pp 434-446 (2021)
Prostate cancers are considered “cold” tumors characterized by minimal T cell infiltrates, absence of a type I interferon (IFN) signature, and the presence of immunosuppressive cells. This non-inflamed phenotype is likely responsible for the lack
Publikováno v:
Clinical Cancer Research. 27:689-703
Therapeutic cancer vaccines, an exciting development in cancer immunotherapy, share the goal of creating and amplifying tumor-specific T-cell responses, but significant obstacles still remain to their success. Here, we briefly outline the principles
Autor:
Burak Gumuscu, Kevin J. Harrington, Hoi-Shen Radcliffe, Lillian L. Siu, Wendy Snyder, Danny Rischin, Beatriz Castelo Fernandez, Ezra E.W. Cohen, Jason Chesney, Anthony Kong, Jonathan D. Cheng, Nicolas Mach
Publikováno v:
Clinical Cancer Research, Vol. 26, No 19 (2020) pp. 5153-5161
Purpose: The prognosis for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is poor, and only a minority of patients benefit from checkpoint immunotherapy. Talimogene laherparepvec (T-VEC), an oncolytic immunoth
Autor:
F. Stephen Hodi, Kevin J. Harrington, Archie N. Tse, David C. Madoff, Jason J. Luke, Andrea Marie Perrone, Lawrence H. Schwartz, Anuradha D. Khilnani, Robert H.I. Andtbacka, Aurélien Marabelle, Gregory V. Goldmacher
Publikováno v:
Journal of Clinical Oncology
3141 Background: The approval of intratumoral (IT) immunotherapy for metastatic melanoma and the active development of numerous novel IT drugs have created a need for standardized evaluation of response to this unique treatment strategy. The Response
Autor:
Joan N. Kyula, Gabriella Baker, David Mansfield, Matthew Chiu, Anna Wilkins, Kevin J. Harrington, Eva Crespo-Rodriguez, Edward Armstrong, Alan Melcher, Martin McLaughlin, Fiona McDonald, Vicki Jennings, Victoria Roulstone, Shane Foo, Malin Pedersen, Galabina Bozhanova, Lorna Grove, Emmanuel C Patin
Publikováno v:
Expert Opinion on Biological Therapy. 20:635-652
Introduction: Immune checkpoint inhibitors (ICI) have dramatically improved the outcome for cancer patients across multiple tumor types. However the response rates to ICI monotherapy remain relativ...
Autor:
Jeffery S. Russell, Shanmugasundaram Ramkumar, Everett E. Vokes, Robert L. Ferris, Makoto Tahara, Maura L. Gillison, Lisa Licitra, Mark Lynch, Robert I. Haddad, Joël Guigay, Caroline Even, Nabil F. Saba, Kevin J. Harrington, Fernando Concha-Benavente, Jérôme Fayette, Li Li, Peter Brossart, George R. Blumenschein, A. Dimitrios Colevas
Publikováno v:
Clin Cancer Res
Purpose: Cetuximab, which modulates immune responses, may affect the efficacy of subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior cetuximab exposure, in patients with recurrent or metastatic (R/M) squamous cell carcinoma
Autor:
Jérôme Fayette, Vijayvel Jayaprakash, Kevin J. Harrington, Robert L. Ferris, Li Li, Maura L. Gillison, Peter Brossart, Nabil F. Saba, Joël Guigay, Lisa Licitra, Naomi Kiyota, George R. Blumenschein
Publikováno v:
Oral oncology
Objectives: Many patients with squamous cell carcinoma of the head and neck (SCCHN) are ≥65 years old; comorbidities and other age-related factors may affect their ability to tolerate traditional chemotherapy. Nivolumab is the only immunotherapy to
Autor:
Kate Newbold, Shreerang Bhide, Alan Melcher, Amy Trinh, KH Wong, Pablo Nenclares, Lucinda Gunn, Heba Soliman, Mateo Bover, Kevin J. Harrington, Christopher M. Nutting, Isla Leslie, Derfel Ap Dafydd
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
BackgroundPrevious studies have suggested that inflammatory markers (neutrophil-to-lymphocyte ratio (NLR), lactate dehydrogenase (LDH) and fibrinogen) are prognostic biomarkers in patients with a variety of solid cancers, including those treated with
Autor:
Jennifer Kingston, Anna Wilkins, Anguraj Sadanandam, Hannah Bye, David Mansfield, Jessica A. Downs, Elisa Fontana, A Noshirwani, Fiona Errington-Mais, Yatish Patil, Magnus T. Dillon, Katharina von Loga, Paul Carter, Kevin J. Harrington, Gift Nyamundanda, Daniel Bottomley, David Sebag-Montefiore, Sandra Demaria, Nicholas P. West, Chanthirika Ragulan, E Tinkler-Hundal, Alan Melcher
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
BackgroundRectal cancers show a highly varied response to neoadjuvant radiotherapy/chemoradiation (RT/CRT) and the impact of the tumor immune microenvironment on this response is poorly understood. Current clinical tumor regression grading systems at
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::052136d6546eada06fa12d3ecaa8e106
https://eprints.whiterose.ac.uk/170165/30/e001717.full.pdf
https://eprints.whiterose.ac.uk/170165/30/e001717.full.pdf